Approaches to rheumatoid arthritis in 2000

Current Opinion in Rheumatology

Volumn 13, Issue 3, 2001, Pages 193-201

  Wollheim, Frank A ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; GAMMA INTERFERON; LECTIN; LEFLUNOMIDE; NAPROXEN; ROFECOXIB; SERUM AMYLOID A; TUMOR NECROSIS FACTOR;

CLINICAL TRIAL; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GENETIC POLYMORPHISM; HUMAN; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS;

EID: 0035025095     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200105000-00008     Document Type: Review

References (113)

1. 1 Riise T, Jacobsen BK, Gran JT: Incidence and prevalence of rheumatoid arthritis in the county of Troms, northern Norway. J Rheumatol 2000, 27:1386-1389.
2. 2 Simonsson M, Bergman S, Jacobson LTH, et al.: The prevalence of rheumatoid arthritis in Sweden. Scand J Rheumatol 1999, 28:340-343.
3. 3 Saraux A, Guedes C, Allain J, et al.: Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Societe de Rhumatologie de l'Ouest. J Rheumatol 1999, 26:2622-2627.
4. 4 Shichikawa K, Inoue K, Hirota S, et al.: Changes in the incidence and prevalence of rheumatoid arthritis in Kamitonda, Wakayama, Japan, 1965-1996. Ann Rheum Dis 1999, 58:751-756.
5. 5 Wollheim FA. The prevalence of rheumatoid arthritis in Sweden. Scand J Rheumatol 2000, 29:204-205.
6. 6 Kaipiainen-Seppä T, Aho K: Incidence of chronic inflammatory joint diseases in Finland in 1995. J Rheumatol 2000, 27:94-100. This report provides longitudinal data based on 5 of 21 Finnish hospital districts, covering 1,000,000 individuals, and provides convincing data in support of increase in age at onset.
7. 7 Sokka T, Möttönen T, Hannonen P: Mortality in early "sawtooth" treated rheumatoid arthritis patients during the first 8-14 years. Scand J Rheumatol 1999, 28:282-287.
8. 8 Gabriel SE, Crowson CS, O'Fallon WM: Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol 1999, 26:2529-2533.
9. 9 Glennas A, Kvien TK, Andrup O, et al.: Recent onset arthritis in the elderly: a 5 year longitudinal observational study. J Rheumatol 2000, 27:101-108.
10. 10 Kroot EJ, van Leeuwen MA, van Rijswijk MH, et al.: No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann Rheum Dis 2000, 59:954-958.
11. 11 Lindqvist E, Eberhardt K: Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann Rheum Dis 1999, 58:11-14.
12. 12 Wållberg-Jonsson S, Johansson H, Ohman ML, et al.: Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset. J Rheumatol 1999, 26:2562-2571.
13. 13 Dai L, Lamb DJ, Leake DS, et al.: Evidence for oxidised low density lipoprotein in synovial fluid from rheumatoid arthritis patients. Free Radic Res 2000, 32:479-486. This is an important study confirming the presence of oxidized low-density lipoproteins in synovial fluid in RA patients with possible atherogenic effects.
14. 14 Wållberg-Jonsson S, Cederfelt M, Rantapåå Dahlqvist S: Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study. J Rheumatol 2000, 27:71-75. This careful study points to the elevated blood levels of vWf and plasminogen activator inhibitor 1 and their possible role in the atherogenesis of RA.
15. 15 Park YB, Lee SK, Lee WK, et al.: Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999, 26:1701-1704.
16. 16 Mello SB, Barros DM, Silva AS, et al.: Methotrexate as a preferential cyclooxygenase 2 inhibitor in whole blood of patients with rheumatoid arthritis, Rheumatology (Oxford) 2000, 39:533-536.
17. 17 Landewe RB, van den Borne BE, Breedveld FC, et al.: Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 2000, 355:1616-1617.
18. 18 Krause D, Schleusser B, Herborn G, et al.: Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000, 43:14-21.
19. 19 Gonzalez-Lopez L, Gamez-Nava JI, Jhangri G, et al.: Decreased progression to rheumatoid arthritis or other connective tissue diseases inpatients with palindromic rheumatism treated with antimalarials. J Rheumatol 2000, 27:41-46.
20. 20 Graudal N, Tarp U, Jurik AG, Galloe AM, et al.: Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate, and hemoglobin: long-term course and association to radiographic progression. J Rheumatol 2000, 27:47-57.
21. 21 Kim JM, Weisman MH: When does rheumatoid arthritis begin and why do we need to know? Arthritis Rheum 2000, 43:473-484.
22. 22 Isenberg DA, Young A: IgG glycosylation status as a clinical predictor of rheumatoid arthritis: comment on the article by Kim and Weisman. Arthritis Rheum 2000, 43:2617-2618.
23. 23 Goldbach-Mansky R, Lee J, McCoy A, et al.: Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000, 2:236-243. This transatlantic cooperative study compares the performance of several new RA related autoantibodies, including a group with specificity for citrullinated peptides. It is concluded that of 238 patients, 101 had a positive response to at least one of the antibodies.
24. 24 Aho K, Palosuo T, Heliovaara M, et al.: Antifilaggrin antibodies within "normal" range predict rheumatoid arthritis in a linear fashion. J Rheumatol 2000, 27:2743-2746.
25. 25 Aho K, Palosuo T, Knekt P, et al.: Serum C-reactive protein does not predict rheumatoid arthritis. J Rheumatol 2000, 27:1136-1138.
26. 26 Cunnane G, Grehan S, Geoghegan S, et al.: Serum amyloid A in the assessment of early inflammatory arthritis. J Rheumatol 2000, 27:58-63.
27. 27 O'Hara R, Murphy EP, Whitehead AS, et al.: Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res 2000, 2:142-144.
28. 28 Harvey S, Whaley J, Eberhardt K: The relation between serum levels of YKL-40 and disease progression in patients with early rheumatoid arthritis. Scand J Rheumatol 2000, 29:391-393.
29. 29 Vos K, Miltenburg AM, van Meijgaarden KE, et al.: Cellular immune response to human cartilage glycoprotein-39 (HC gp-39)-derived peptides in rheumatoid arthritis and other inflammatory conditions. Rheumatology (Oxford) 2000, 39:1326-1331.
30. 30 Sekine T, Masuko-Hongo K, Matsui T, et al.: Recognition of YKL-39, a human cartilage related protein, as a target antigen in patients with rheumatoid arthritis. Ann Rheum Dis 2001, 60:49-54.
31. 31 Ribbens C, Andre B, Kaye O, et al.: Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthritides whether erosive or not. Rheumatology (Oxford) 2000, 39:1357-1365.
32. 32 Penglis PS, Bond C, Humphreys I, et al.: Genetic susceptibility and the link between cat exposure and rheumatoid arthritis. Semin Arthritis Rheum 2000, 30:111-120.
33. 33 Neth O, Jack DL, Dodds AW, et al.: Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 2000, 68:688-693.
34. 34 Graudal NA, Homann C, Madsen HO, et al.: Mannan binding lectin in rheumatoid arthritis: a longitudinal study. J Rheumatol 1998, 25:629-635.
35. 35 Graudal NA, Madsen HO, Tarp U, et al.: The association of variant mannose-binding lectin genotypes with radiographic outcome in rheumatoid arthritis. Arthritis Rheum 2000, 43:515-521. This report confirms an association of MBL polymorphism not only with susceptibility but also with severity in a very carefully observed patient population followed up for as long as three decades.
36. 36 Ip WK, Lau YL, Chan SY, et al.: Mannose-binding lectin and rheumatoid arthritis in southern Chinese. Arthritis Rheum 2000, 43:1679-1687. This report supplements and extends Neth et al. [33] and identifies genetic defects related to susceptibility and severity in a different ethnic population.
37. 37 Khani-Hanjani A, Lacaille D, Hoar D, et al.: Association between dinucleotide repeat in non-coding region of interferon-gamma gene and susceptibility to, and severity of, rheumatoid arthritis. Lancet 2000, 356:820-825.
38. 38 Crilly A, Maiden N, Capell HA, et al.: Predictive value of interleukin 1 gene polymorphisms for surgery. Ann Rheum Dis 2000, 59:695-699.
39. 39 Griffiths B, Situnayake RD, Clark B, et al.: Racial origin and its effect on disease expression and HLA-DRB1 types in patients with rheumatoid arthritis: a matched cross-sectional study. Rheumatology (Oxford) 2000, 39:857-864. This article nicely demonstrates that damage and disability but not signs of inflammation segregate along ethnic borders.
40. 40 Balsa A, Minaur NJ, Pascual-Salcedo D, et al.: Class II MHC antigens in early rheumatoid arthritis in Bath (UK) and Madrid (Spain). Rheumatology (Oxford) 2000, 39:544-849.
41. 41 Martinez A, Fernandez-Arquero M, Pascual-Salcedo D, et al.: Primary association of tumor necrosis factor-region genetic markers with susceptibility to rheumatoid arthritis. Arthritis Rheum 2000, 43:1366-1370.
42. 42 Hajeer AH, Dababneh A, Makki RF, et al.: Different gene loci within the HLA-DR and TNF regions are independently associated with susceptibility and severity in Spanish rheumatoid arthritis patients. Tissue Antigens 2000, 55:319-325.
43. 43 Castro F, Acevedo E, Ciusano E, et al.: Tumour necrosis factor micro-satellites and HLA DRB1*, DQA1* and DQB1* alleles in Peruvian patients with rheumatoid arthritis. Ann Rheum Dis 2001, in press.
44. 44 Lacki JK, Moser R, Korczowska I, et al.: TNF-alpha gene polymorphism does not affect the clinical and radiologic outcome of rheumatoid arthritis. Rheumatol Int 2000, 19:137-140.
45. 45 Gregersen PK, Silver J, Winchester RJ: The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987, 30:1205-1213.
46. 46 Weyand CM, Goronzy JJ: Association of MHC and rheumatoid arthritis: HLA polymorphisms in phenotypic variants of rheumatoid arthritis. Arthritis Res 2000, 2:212-216. A well-written review summarizing a complex mass of information in a way palatable to the clinical mind. Not everyone may share some of the author's interpretations, but the reader will be forced to reflect.
47. 47 Coakley G, Brooks D, Iqbal M, et al.: Major histocompatibility complex haplotypic associations in Felty's syndrome and large granular lymphocyte syndrome are secondary to allelic association with HLA-DRB1*0401. Rheumatology (Oxford) 2000, 39:393-398.
48. 48 Mattey DL, Gonzalez-Gay MA, Hajeer AH, et al.: Association between HLA-DRB1*15 and secondary Sjogren's syndrome in patients with rheumatoid arthritis. J Rheumatol 2000, 27:2611-2616.
49. 49 Mattey DL, Hassell AB, Dawes PT, et al.: Related influence of polymorphism in the manganese superoxide dismutase locus on disease outcome in rheumatoid arthritis: evidence for interaction with glutathione S-transferase genes. Arthritis Rheum 2000, 43:869-864.
50. 50 Fife MS, Fisher SA, John S, et al.: Multipoint linkage analysis of a candidate gene locus in rheumatoid arthritis demonstrates significant evidence of linkage and association with the corticotropin-releasing hormone genomic region. Arthritis Rheum 2000, 43:1673-1678.
51. 51 Baerwald CG, Mok CC, Tickly M, et al.: Corticotropin releasing hormone (CRH) promoter polymorphisms in various ethnic groups of patients with rheumatoid arthritis. Z Rheumatol 2000, 59:29-34.
52. 52 Marra CA, Esdaile JM, Sunday H, et al.: The cost of COX inhibitors: how selective should we be? J Rheumatol 2000, 27:2731-2733.
53. 53 Wollheim FA. Selective cox-2 inhibition in man: therapeutic breakthrough or cosmetic advance? Rheumatology (Oxford) 2000, 39:935-938.
54. 34 Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 2000, 284:1247-1255. This study lends strong support to the improved gastrointestinal safety of celecoxib in comparison with two nonselective NSAIDs. It is, however, also evident that the combination of low-dose aspirin with high-dose celecoxib eliminates most of this advantage.
55. 55 Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343:1520-1528. Improved gastrointestinal safety of rofecoxib compared with naproxen is convincingly documented. Furthermore, the increased rate of myocardial infarction in the rofecoxib arm of the study needs close attention. Patients with indications for low-dose aspirin were, according the protocol, excluded from this study.
56. 56 Crofford LJ, Oates JC, McCune WJ, et al.: Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: a report of four cases. Arthritis Rheum 2000, 43:1891-1896. It is important to be vigilant in identifying at-risk patients who should not be exposed to celecoxib or other selective cox-2 inhibitors.
57. 57 Karim A, Tolbert D, Piergies A, et al.: Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects. J Clin Pharmacol 2000, 40:655-663.
58. 58 Perazella MA, Eras J: Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000, 35:937-940.
59. 59 Whelton A, Schulman G, Wallemark C, et al.: Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000, 160:1465-1470.
60. 60 Swan SK, Rudy DW, Lasseter KC, et al.; Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: a randomized, controlled trial. Ann Intern Med 2000, 133:1-9.
61. 61 Komhoff M, Wang JL, Cheng HF, et al.: Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int 2000, 57:414-422.
62. 62 Breedveld FC, Dayer JM: Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000, 59:841-849.
63. 63 Emery P, Breedveld FC, Lemmel EM, et al.: A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:655-665.
64. 64 Tugwell P, Wells G, Strand V, et al.: Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000, 43:506-514.
65. 65 Sharp JT, Strand V, Leung H, et al.: Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000, 43:495-505.
66. 66 Kraan MC, de Koster BM, Elferink JG, et al.: Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum 2000, 43:1488-1495.
67. 67 Kraan MC, Reece RJ, Barg EC, et al.: Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000, 43:1820-1830.
68. 68 Auer J, Hinterreiter M, Allinger S. et al.: Severe pancytopenia after leflunomide in rheumatoid arthritis. Acta Med Austriaca 2000, 27:131-132.
69. 69 O'Dell JR, Haire CE, Erikson N, et al.: Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996, 334:1287-1291.
70. 70 Neva MH, Kauppi MJ, Kautiainen H, et al.: Combination drug therapy retards the development of rheumatoid atlantoaxial subluxations. FIN-RACo Trial Group. Arthritis Rheum 2000, 43:2397-2401.
71. 71 Proudman SM, Conaghan PG, Richardson C, et al.: Treatment of poor-prognosis early rheumatoid arthritis: a randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 2000, 43:1809-1819.
72. 72 Minghetti PP, Blackburn WD Jr: Effects of sulfasalazine and its metabolites on steady state messenger RNA concentrations for inflammatory cytokines, matrix metalloproteinases, and tissue inhibitors of metalloproteinase in rheumatoid synovial fibroblasts. J Rheumatol 2000, 27:653-660.
73. 73 Gunnarsson I, Nordmark B, Hassan Bakri A, et al.: Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment: the role of IL-10 and HLA. Rheumatology (Oxford) 2000, 39:886-893.
74. 74 Alarcon GS, Bartolucci AA: Radiographic assessment of disease progression in rheumatoid arthritis patients treated with methotrexate or minocycline. J Rheumatol 2000, 27:530-534.
75. 75 Tsakonas E, Fitzgerald AA, Fitzcharles MA, et al.: Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol 2000, 27:623-629.
76. 76 Borg G, Allander E, Berg E, et al.: Auranofin treatment in early rheumatoid arthritis may postpone early retirement: results from a 2-year double blind trial. J Rheumatol 1991, 18:1015-1020.
77. 77 Egsmose C, Lund B, Borg G, et al.: Patients with rheumatoid arthritis benefit from early 2nd line therapy; 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995, 22:2208-2213.
78. 78 O'Dell JR, Paulsen G, Haire CE, et al.: Treatment of early seropositive rheumatoid arthritis with minocycline: four-year followup of a double-blind, placebo-controlled trial. Arthritis Rheum 1999, 42:1691-1695.
79. 79 Horai R, Saijo S, Tanioka H, et al.: Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000;191:313-20. An exciting new model with several features of RA such as erosive polyarthritis, antibody formation, cytokine disturbances, and requirement for genetic susceptibility.
80. 80 Barrera P, van der Laken CJ, Boerman OC, et al.: Radiolabeled interleukin-1 receptor antagonist for detection of synovitis in patients with rheumatoid arthritis, Rheumatology (Oxford) 2000, 39:870-874.
81. 81 Jiang Y, Genant HK, Watt I, et al.: A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000, 43:1001-1009. This study showed significant retardation of joint damage progression even after 6 months in patients with fairly advanced disease.
82. 82 Bresnihan B, Alvaro-Gracia JM, Cobby M, et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998, 41:2196-2204.
83. 83 Choy EH, Connolly DJ, Rapson N, et al.: Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology (Oxford) 2000, 39:1139-1146.
84. 84 Lipsky PE, van der Heijde DM, St Clair EW, et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343:1594-1602. The radiographic progression was analyzed by a modified Sharp index and showed impressive retardation in all treatment arms and, interestingly, indicated damage retardation even in patients who did not respond clinically.
85. 85 Drossaers-Bakker KW, Amesz E, Zwinderman AH, et al.: A comparison of three radiologic scoring systems for the long-term assessment of rheumatoid arthritis: findings of an ongoing prospective inception cohort study of 132 women followed up for a median of twelve years. Arthritis Rheum 2000, 43:1465-1472.
86. 86 Hulsmans HM, Jacobs JW, van der Heijde DM, et al.: The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 2000, 43:1927-1940.
87. 87 Lassere M: Pooled metaanalysis of radiographic progression: comparison of Sharp and Larsen methods. J Rheumatol 2000, 27:269-275.
88. 88 Sokka T, Kankainen A, Hannonen P: Scores for functional disability in patients with rheumatoid arthritis are correlated at higher levels with pain scores than with radiographic scores. Arthritis Rheum 2000, 43:386-389.
89. 89 Scott DL, Pugner K, Kaarela K, et al.: The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:122-132.
90. 90 Drossaers-Bakker KW, Kroon HM, Zwinderman AH, et al.: Radiographic damage of large joints in long-term rheumatoid arthritis and its relation to function. Rheumatology (Oxford) 2000, 39:998-1003.
91. 91 Sharp JT, Gardner JC, Bennett EM: Computer-based methods for measuring joint space and estimating erosion volume in the finger and wrist joints of patients with rheumatoid arthritis. Arthritis Rheum 2000, 43:1378-1386. Computerized measurement of erosion volume shows promise.
92. 92 Cimmino MA, Bountis C, Silvestri E, et al: An appraisal of magnetic resonance imaging of the wrist in rheumatoid arthritis. Semin Arthritis Rheum 2000, 30:180-195.
93. 93 Gasson J, Gandy SJ, Hutton CW, et al.: Magnetic resonance imaging of rheumatoid arthritis in metacarpophalangeal joints. Skeletal Radiol 2000, 29:324-334.
94. 94 Sugimoto H, Takeda A, Hyodoh K, Early-stage rheumatoid arthritis: prospective study of the effectiveness of MR imaging for diagnosis. Radiology 2000, 216:569-575.
95. 95 Klarlund, M, Ostergaard M, Jensen KE, et al.: Magnetic resonance imaging, radiography, and scintigraphy of the finger joints: one year follow up of patients with early arthritis. The TIRA Group. Ann Rheum Dis 2000, 59:521-528.
96. 96 Klarlund M, Ostergaard M, Rostrup E, et al.: Dynamic magnetic resonance imaging of the metacarpophalangeal joints in rheumatoid arthritis, early unclassified polyarthritis, and healthy controls. Scand J Rheumatol 2000, 29:108-115. These carefully designed studies clearly show MRI to provide additional information supplementing routine radiology and physical examination.
97. 97 Huang J, Stewart N, Crabbe J, et al.: A 1-year follow-up study of dynamic magnetic resonance imaging in early rheumatoid arthritis reveals synovltis to be increased in shared epitope-positive patients and predictive of erosions at 1 year. Rheumatology (Oxford) 2000, 39:407-416.
98. 98 Hamilton JD, Gordon MM, McInnes IB, et al.: Improved medical and surgical management of cervical spine disease in patients with rheumatoid arthritis over 10 years. Ann Rheum Dis 2000, 59:434-438.
99. 99 Reijnierse M, Breedveld FC, Kroon HM, et al.: Are magnetic resonance flexion views useful in evaluating the cervical spine of patients with rheumatoid arthritis? Skeletal Radiol 2000, 29:85-89.
100. 100 Jacobsen EA, Riise T, MRI of cervical spine with flexion and extension used in patients with rheumatoid arthritis. Scand J Rheumatol 2000, 29:249-254.
101. 101 Wakefield RJ, Gibbon WW, Conaghan PG, et al.: The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthritis Rheum 2000, 43:2762-2770. This is innovative information, and if confirmed it may change clinical practice considerably.
102. 102 Uitz E, Fransen J, Langenegger T, et al.: Clinical quality management in rheumatoid arthritis: putting theory into practice. Swiss clinical quality management in rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:542-549.
103. 103 Young A, Dixey J, Cox N, et al.: How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the early RA study. Rheumatology (Oxford) 2000, 39:603-611.
104. 104 MacLean CH, Louie R, Leake B, et al.: Quality of care for patients with rheumatoid arthritis. JAMA 2000, 284:984-992.
105. 105 Hafner J, Schneider E, Burg G, et al.: Management of leg ulcers in patients with rheumatoid arthritis or systemic sclerosis: the importance of concomitant arterial and venous disease. J Vasc Surg 2000, 32:322-329.
106. 106 Jonsson T, Thorsteinsson J, Valdimarsson H: Elevation of only one rheumatoid factor isotype is not associated with increased prevalence of rheumatoid arthritis: a population based study. Scand J Rheumatol 2000, 29:190-191.
107. 107 Halldorsdottir HD, Jonsson T, Thorsteinsson J, et al.: A prospective study on the incidence of rheumatoid arthritis among people with persistent increase of rheumatoid factor. Ann Rheum Dis 2000, 59:149-151.
108. 108 Kroot EJ, de Jong BA, van Leeuwen MA, et al.: The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000, 43(8):1831-1835. This is an important observation that, however, needs confirmation in other cohorts.
109. 109 Wolfe F: The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol 2000, 27:630-637.
110. 110 Haugeberg G, Uhlig T, Falch JA, et al.: Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninety-four patients in the County Rheumatoid Arthritis Register. Arthritis Rheum 2000, 43:2776-2784.
111. 111 Paulus HE, Di Primeo D, Sanda M, et al.: Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis. J Rheumatol 2000, 27:1632-1637.
112. 112 Plant MJ, Williams AL, O'Sullivan MM, et al.: relation between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 2000, 43:1473-1477.
113. 113 Dieppe P, Szebenyi B: Evidence based rheumatology. J Rheumatol 2000, 27:4-7.